Our vision is to be a trusted leader in changing the practice of medicine. A big part of gaining this trust is being transparent – being open and clearly disclosing what we do, how we work, where we are successful. This applies across all aspects of our business around the world.
In order to allow everyone to get a better look at our business and how we operate, we publish several key pieces of information:
Corporate Responsibility Performance Report
Novartis has a strong history of corporate responsibility (CR) activities, and transparent reporting is a central part of our commitment. We issue an annual Corporate Responsibility Performance Report, which consolidates the company’s CR reporting and details our progress against our targets. It is based on the Global Reporting Initiative G4 guidelines, with disclosure at “comprehensive” level.
Our stakeholders have important questions about our business practices in the United States, including our approach to price adjustments, patient assistance, investment in research and development, and marketing. This report aims to help answer those questions.
Novartis seeks to collaborate with Healthcare Professionals and Healthcare Organizations in the interest of patients. As an industry we make payments or ”transfers of value” to Healthcare Professionals and Organizations to compensate them for the time spent working with us. In several countries, we publish payments to Healthcare Professionals and Organizations in line with local laws or regulations.
Novartis works with many organizations that advocate for patients around the world. These organizations play a crucial role by informing and supporting patients, as well as safeguarding the rights of patients and caregivers. Each year we disclose our relationships with patient organizations online.
Novartis actively participates in public policy debates affecting healthcare and our business. This includes engaging in constructive dialogue with policymakers and other external stakeholders with the intent to represent the perspective of Novartis in the policy making process, as well as making financial contributions to support political dialogue on issues of relevance to the company.
Novartis informs the public about the results of its interventional clinical trials for innovative compounds, regardless of the outcome. The results of Novartis clinical trials are made publicly available through peer-reviewed publications and posting of results on the Novartis clinical trial results database and other online public databases.
Novartis needs animal research to find innovative, safe and life-saving medicines for patients. We are committed to transparent reporting of the numbers of animals needed for research and development purposes.
We take our responsibility to protect the environment seriously. As part of that commitment, each year we disclose our submissions to the CDP on climate change and water. CDP is a not-for-profit charity that runs the global disclosure system for investors, companies, cities, states and regions to manage their environmental impacts.
Novartis seeks to collaborate with Healthcare Professionals and Healthcare Organizations in interest of patients. As an industry we make payments or ‘transfers of value’ to Healthcare Professionals and Organizations to compensate them for the time spent working with us.